{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T16:24:03Z","timestamp":1791563043521,"version":"4.3.4"},"reference-count":31,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100014549","name":"Stanford Cancer Institute","doi-asserted-by":"publisher","award":["P30CA124435"],"award-info":[{"award-number":["P30CA124435"]}],"id":[{"id":"10.13039\/100014549","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jtct.2025.08.014","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T23:15:50Z","timestamp":1756336550000},"page":"1006.e1-1006.e11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["The Impact of Anti-CD38 Monoclonal Antibody Therapy on Stem-Cell Mobilization Yields in Patients With Newly Diagnosed Multiple Myeloma (NDMM) Referred From Community and Academic Oncology Practices: Single Center, Real World Data 2021-2024"],"prefix":"10.1016","volume":"31","author":[{"given":"Dilek","family":"Uzun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeddeo Michael","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6337-9079","authenticated-orcid":false,"given":"Alexandria","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Tamaresis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Domingo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Arai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe Araya","family":"Ventura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Rocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushma","family":"Bharadwaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Lowsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Rezvani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parveen","family":"Shiraz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Shizuru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Kai","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitomi","family":"Hosoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surbhi","family":"Sidana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Miklos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori","family":"Muffly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7698-5934","authenticated-orcid":false,"given":"Lekha","family":"Mikkilineni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.jtct.2025.08.014_bib0001","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1038\/leu.2009.127","article-title":"International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100)","volume":"23","author":"Giralt","year":"2009","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.jtct.2025.08.014_bib0002","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2204925","article-title":"Triplet therapy, transplantation, and maintenance until progression in myeloma","volume":"387","author":"Richardson Paul","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jtct.2025.08.014_bib0003","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0889-8588(05)70419-6","article-title":"Standard therapy versus autologous transplantation in multiple myeloma","volume":"11","author":"Attal","year":"1997","journal-title":"Hematol Oncol Clin North Am"},{"issue":"14","key":"10.1016\/j.jtct.2025.08.014_bib0004","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jtct.2025.08.014_bib0005","doi-asserted-by":"crossref","first-page":"174.e1","DOI":"10.1016\/j.jtct.2022.11.029","article-title":"Stem cell mobilization yields with daratumumab- and lenalidomide-containing quadruplet induction therapy in newly diagnosed multiple myeloma: findings from the MASTER and GRIFFIN trials","volume":"29","author":"Chhabra","year":"2023","journal-title":"Transplant Cellr Ther"},{"issue":"4","key":"10.1016\/j.jtct.2025.08.014_bib0006","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.jtct.2025.08.014_bib0007","doi-asserted-by":"crossref","first-page":"e890","DOI":"10.1016\/S2352-3026(23)00236-3","article-title":"Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial","volume":"10","author":"Costa","year":"2023","journal-title":"Lancet Haematol"},{"issue":"Supplement 1","key":"10.1016\/j.jtct.2025.08.014_bib0008","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-177546","article-title":"Results of the phase III randomized iskia trial: isatuximab-carfilzomib-lenalidomide-dexamethasone vs carfilzomib-lenalidomide-dexamethasone as pre-transplant induction and post-transplant consolidation in newly diagnosed multiple myeloma patients","volume":"142","author":"Gay","year":"2023","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.jtct.2025.08.014_bib0009","doi-asserted-by":"crossref","first-page":"e810","DOI":"10.1016\/S2352-3026(22)00263-0","volume":"9","author":"Goldschmidt","year":"2022","journal-title":"Lancet Haematol"},{"issue":"8","key":"10.1016\/j.jtct.2025.08.014_bib0010","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/S1470-2045(24)00282-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial","volume":"25","author":"Moreau","year":"2024","journal-title":"Lancet Oncol"},{"issue":"10192","key":"10.1016\/j.jtct.2025.08.014_bib0011","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jtct.2025.08.014_bib0012","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1186\/s12885-023-11507-9","article-title":"Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: a single centre experience from the GMMG-HD6 and -HD7 trials","volume":"23","author":"Kauer","year":"2023","journal-title":"BMC Cancer"},{"issue":"13","key":"10.1016\/j.jtct.2025.08.014_bib0013","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1080\/10428194.2023.2253479","article-title":"Impact of daratumumab on stem cell mobilization and collection, engraftment and early post-transplant complications among multiple myeloma patients undergoing autologous stem cell transplantation","volume":"64","author":"Eleutherakis Papaiakovou","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.jtct.2025.08.014_bib0014","doi-asserted-by":"crossref","first-page":"610","DOI":"10.3324\/haematol.2022.281610","article-title":"Impact of daratumumab-based induction on stem cell collection parameters in Swedish myeloma patients","volume":"108","author":"Lemonakis","year":"2023","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.jtct.2025.08.014_bib0015","first-page":"340.e1","article-title":"Stem cell mobilization for multiple myeloma patients receiving daratumumab-based induction therapy: a real- world experience","volume":"29","author":"Thurlapati","year":"2023","journal-title":"Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and Cellular Therapy"},{"key":"10.1016\/j.jtct.2025.08.014_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.tracli.2025.02.001","article-title":"Impact of quadruplet induction therapy on stem cell mobilization yields in newly diagnosed multiple myeloma","author":"Beechinor","year":"2025","journal-title":"Transfus Clin Biol"},{"issue":"6","key":"10.1016\/j.jtct.2025.08.014_bib0017","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/s41409-024-02260-z","article-title":"Effect of daratumumab on stem cell yields in patients with newly diagnosed multiple myeloma: a report from the Multiple Myeloma Group","volume":"59","author":"Fazio","year":"2024","journal-title":"Bone Marrow Transplantation"},{"issue":"1","key":"10.1016\/j.jtct.2025.08.014_bib0018","doi-asserted-by":"crossref","DOI":"10.4084\/MJHID.2024.041","article-title":"Impact of daratumumab on stem cell mobilization and transplant in patient with newly diagnosed multiple myeloma: a real word single-centre study","volume":"16","author":"Passucci","year":"2024","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"7","key":"10.1016\/j.jtct.2025.08.014_bib0019","doi-asserted-by":"crossref","first-page":"944","DOI":"10.3390\/ph17070944","article-title":"Impact of anti-CD38 monoclonal antibody therapy on CD34+ hematopoietic stem cell mobilization, collection, and engraftment in multiple myeloma patients\u2014a systematic review","volume":"17","author":"Bigi","year":"2024","journal-title":"Pharmaceuticals"},{"issue":"11","key":"10.1016\/j.jtct.2025.08.014_bib0020","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1111\/trf.17566","article-title":"Steady-state versus chemotherapy-based hematopoietic cell mobilization after anti-CD38-based induction therapy in newly diagnosed multiple myeloma","volume":"63","author":"Teipel","year":"2023","journal-title":"Transfusion"},{"issue":"2","key":"10.1016\/j.jtct.2025.08.014_bib0021","doi-asserted-by":"crossref","first-page":"S377","DOI":"10.1016\/j.jtct.2023.12.528","article-title":"Stem cell mobilization yields with daratumumab (Dara) and lenalidomide(Len)-containing quadruplet induction therapy in patients with newly diagnosed multiple myeloma (NDMM): real world experience","volume":"30","author":"Varga","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"24","key":"10.1016\/j.jtct.2025.08.014_bib0022","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","article-title":"Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group","volume":"127","author":"Sonneveld","year":"2016","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jtct.2025.08.014_bib0023","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.jtct.2025.08.014_bib0024","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/jca.21290","article-title":"Cost-effectiveness of hematopoietic stem cell mobilization strategies including plerixafor in multiple myeloma and lymphoma patients","volume":"28","author":"Tichop\u00e1d","year":"2013","journal-title":"J Clin Apher"},{"issue":"10","key":"10.1016\/j.jtct.2025.08.014_bib0025","doi-asserted-by":"crossref","first-page":"e825","DOI":"10.1016\/S2352-3026(23)00217-X","article-title":"Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial","volume":"10","author":"Voorhees","year":"2023","journal-title":"The Lancet Haematology"},{"issue":"4","key":"10.1016\/j.jtct.2025.08.014_bib0026","doi-asserted-by":"crossref","DOI":"10.1002\/jca.22138","article-title":"A multi-institutional survey of apheresis services among institutions in the United States","volume":"39","author":"Yurtsever","year":"2024","journal-title":"J Clin Apher"},{"issue":"2","key":"10.1016\/j.jtct.2025.08.014_bib0027","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/ejh.14008","article-title":"Failure of mobilization of hematopoietic stem cells associated with elevated serum levels of anti-CD38 monoclonal antibody","volume":"111","author":"Seth","year":"2023","journal-title":"Eur J Haematol"},{"issue":"4","key":"10.1016\/j.jtct.2025.08.014_bib0028","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1111\/bjh.19141","article-title":"Insight into the mechanism of CD34+ cell mobilisation impairment in multiple myeloma patients treated with anti-CD38 therapy","volume":"204","author":"Venglar","year":"2024","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.jtct.2025.08.014_bib0029","article-title":"Effects of daratumumab on hematopoietic stem cells in patients with multiple myeloma who are planned to receive autologous transplantation: what's the relevance?","volume":"16","author":"Sgherza","year":"2024","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"4","key":"10.1016\/j.jtct.2025.08.014_bib0030","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/s41591-023-02273-z","article-title":"Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial","volume":"29","author":"Crees","year":"2023","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.jtct.2025.08.014_bib0031","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.bbmt.2015.03.002","article-title":"Hematopoietic stem cell transplantation for multiple myeloma: guidelines from the american society for blood and marrow transplantation","volume":"21","author":"Shah","year":"2015","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725013806?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725013806?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T21:34:30Z","timestamp":1772919270000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636725013806"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":31,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2666636725013806"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2025.08.014","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Impact of Anti-CD38 Monoclonal Antibody Therapy on Stem-Cell Mobilization Yields in Patients With Newly Diagnosed Multiple Myeloma (NDMM) Referred From Community and Academic Oncology Practices: Single Center, Real World Data 2021-2024","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2025.08.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc. on behalf of The American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}